{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:05:49Z","timestamp":1753736749613},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00115-020-00870-8","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T14:05:37Z","timestamp":1582121137000},"page":"318-323","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genspezifische Therapieans\u00e4tze bei Muskelerkrankungen"],"prefix":"10.1007","volume":"91","author":[{"given":"Diana","family":"Lehmann Urban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilka","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"issue":"10","key":"870_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/nrm2024","volume":"7","author":"KE Davies","year":"2006","unstructured":"Davies\u00a0KE, Nowak\u00a0KJ (2006) Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 7(10):762\u2013773","journal-title":"Nat Rev Mol Cell Biol"},{"key":"870_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","volume":"16","author":"S Guiraud","year":"2015","unstructured":"Guiraud\u00a0S et\u00a0al (2015) The pathogenesis and therapy of muscular dystrophies. Annu Rev Genomics Hum Genet 16:281\u2013308","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"3","key":"870_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell\u00a0JR et al (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71(3):304\u2013313","journal-title":"Ann Neurol"},{"issue":"9","key":"870_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/sj.embor.7400221","volume":"5","author":"KJ Nowak","year":"2004","unstructured":"Nowak\u00a0KJ, Davies\u00a0KE (2004) Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5(9):872\u2013876","journal-title":"EMBO Rep"},{"issue":"1","key":"870_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi\u00a0C, Wood\u00a0MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9\u201321","journal-title":"Nat Rev Neurol"},{"key":"870_CR6","doi-asserted-by":"crossref","first-page":"175628641877693","DOI":"10.1177\/1756286418776932","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster\u00a0CD, Ludolph\u00a0AC (2018) Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 11:1756286418776932","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"870_CR7","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/hum.2006.061","volume":"18","author":"V Arechavala-Gomeza","year":"2007","unstructured":"Arechavala-Gomeza\u00a0V et al (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18(9):798\u2013810","journal-title":"Hum Gene Ther"},{"issue":"2","key":"870_CR8","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/mt.2011.248","volume":"20","author":"S Cirak","year":"2012","unstructured":"Cirak\u00a0S et al (2012) Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 20(2):462\u2013467","journal-title":"Mol Ther"},{"issue":"22","key":"870_CR9","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim\u00a0AS, Avorn\u00a0J (2016) Approving a\u00a0problematic muscular dystrophy drug: implications for FDA policy. JAMA 316(22):2357\u20132358","journal-title":"JAMA"},{"issue":"3","key":"870_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajmg.a.30617","volume":"134","author":"KM Dent","year":"2005","unstructured":"Dent\u00a0KM et\u00a0al (2005) Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet\u00a0A 134(3):295\u2013298","journal-title":"Am J Med Genet A"},{"issue":"4","key":"870_CR11","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby\u00a0K et\u00a0al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4):477\u2013487","journal-title":"Muscle Nerve"},{"issue":"18","key":"870_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/gt.2008.89","volume":"15","author":"GR Jayandharan","year":"2008","unstructured":"Jayandharan\u00a0GR et al (2008) Strategies for improving the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 15(18):1287\u20131293","journal-title":"Gene Ther"},{"issue":"10","key":"870_CR13","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","volume":"26","author":"D Duan","year":"2018","unstructured":"Duan\u00a0D (2018) Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther 26(10):2337\u20132356","journal-title":"Mol Ther"},{"issue":"1","key":"870_CR14","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.3390\/jpm9010001","volume":"9","author":"Y Shimizu-Motohashi","year":"2019","unstructured":"Shimizu-Motohashi\u00a0Y et al (2019) Restoring dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches. J\u00a0Pers Med 9(1):E1. https:\/\/doi.org\/10.3390\/jpm9010001","journal-title":"J Pers Med"},{"issue":"7","key":"870_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ejhg.2011.23","volume":"19","author":"T Suominen","year":"2011","unstructured":"Suominen\u00a0T et\u00a0al (2011) Population frequency of myotonic dystrophy: higher than expected frequency of myotonic dystrophy type 2 (DM2) mutation in Finland. Eur J Hum Genet 19(7):776\u2013782","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"870_CR16","doi-asserted-by":"publisher","first-page":"pky052","DOI":"10.1093\/jncics\/pky052","volume":"2","author":"R Alsaggaf","year":"2018","unstructured":"Alsaggaf\u00a0R et\u00a0al (2018) Cancer risk in myotonic dystrophy type I: evidence of a\u00a0role for disease severity. JNCI Cancer Spectr 2(4):pky52","journal-title":"JNCI Cancer Spectr"},{"issue":"16","key":"870_CR17","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/ijms20164017","volume":"20","author":"K Reddy","year":"2019","unstructured":"Reddy\u00a0K et\u00a0al (2019) Mitigating RNA toxicity in myotonic dystrophy using small molecules. Int J Mol Sci 20(16):4017","journal-title":"Int J Mol Sci"},{"issue":"33","key":"870_CR18","doi-asserted-by":"publisher","first-page":"13915","DOI":"10.1073\/pnas.0905780106","volume":"106","author":"SA Mulders","year":"2009","unstructured":"Mulders\u00a0SA et al (2009) Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S\u00a0A 106(33):13915\u201313920","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7409","key":"870_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nature11362","volume":"488","author":"TM Wheeler","year":"2012","unstructured":"Wheeler\u00a0TM et\u00a0al (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488(7409):111\u2013115","journal-title":"Nature"},{"issue":"2","key":"870_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1124\/jpet.115.226969","volume":"355","author":"SK Pandey","year":"2015","unstructured":"Pandey\u00a0SK et\u00a0al (2015) Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J\u00a0Pharmacol Exp Ther 355(2):329\u2013340","journal-title":"J Pharmacol Exp Ther"},{"key":"870_CR21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fneur.2018.00349","volume":"9","author":"M Lopez-Morato","year":"2018","unstructured":"Lopez-Morato\u00a0M, Brook\u00a0JD, Wojciechowska\u00a0M (2018) Small molecules which improve pathogenesis of myotonic dystrophy type 1. Front Neurol 9:349","journal-title":"Front Neurol"},{"issue":"1","key":"870_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molcel.2007.07.027","volume":"28","author":"NM Kuyumcu-Martinez","year":"2007","unstructured":"Kuyumcu-Martinez\u00a0NM, Wang\u00a0GS, Cooper\u00a0TA (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28(1):68\u201378","journal-title":"Mol Cell"},{"key":"870_CR23","first-page":"1","volume":"6","author":"I Schneider","year":"2015","unstructured":"Schneider\u00a0I, Zierz\u00a0S (2015) Profile of alglucosidase alfa in the treatment of Pompe disease: safety, efficacy, and patient acceptability. Res Rep Endocr Disord 6:1\u20139","journal-title":"Res Rep Endocr Disord"},{"issue":"3","key":"870_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/mt.2009.305","volume":"18","author":"CS Mah","year":"2010","unstructured":"Mah\u00a0CS et al (2010) Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 18(3):502\u2013510","journal-title":"Mol Ther"},{"issue":"4","key":"870_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/humc.2017.146","volume":"28","author":"M Corti","year":"2017","unstructured":"Corti\u00a0M et al (2017) Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev 28(4):208\u2013218","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"13","key":"870_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm.2019.05.56","volume":"7","author":"BJ Byrne","year":"2019","unstructured":"Byrne\u00a0BJ et\u00a0al (2019) Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Ann Transl Med 7(13):290","journal-title":"Ann Transl Med"},{"issue":"4","key":"870_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1212\/WNL.0000000000001783","volume":"85","author":"R Tawil","year":"2015","unstructured":"Tawil\u00a0R et al (2015) Evidence-based guideline summary: evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology and the practice issues review panel of the American association of neuromuscular & electrodiagnostic medicine. Neurology 85(4):357\u2013364","journal-title":"Neurology"},{"key":"870_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","volume":"8","author":"LM Wallace","year":"2018","unstructured":"Wallace\u00a0LM et al (2018) Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD. Mol Ther Methods Clin Dev 8:121\u2013130","journal-title":"Mol Ther Methods Clin Dev"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-020-00870-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00870-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T02:36:46Z","timestamp":1613702206000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-020-00870-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["870"],"URL":"https:\/\/doi.org\/10.1007\/s00115-020-00870-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"19 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Lehmann Urban und I.\u00a0Schneider geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}